MUNTEANU, R. A.; MOLDOVAN, C. S.; TIGU, A. B.; DRULA, R.; FEDER, R.; MAGDO, L.; JURJ, A.; RADULY, L.; BUDISAN, L.; PIRLOG, R.; MOLDOVAN, A.; ZIMTA, A. A.; BRAICU, C.; PREDA, A.; MUNTEANU, V.; ROMITAN, M.; GULEI, D.; CIULEANU, T. E. 5-Azacytidine treatment inhibits the development of lung cancer models via epigenetic reprogramming and activation of cellular pathways with anti-tumor activity. Medicine and Pharmacy Reports, [S. l.], v. 97, n. 4, p. 488–506, 2024. DOI: 10.15386/mpr-2777. Disponível em: https://medpharmareports.com/index.php/mpr/article/view/2777. Acesso em: 18 jul. 2025.